Biopharma Credit Dividends - BPCR

Biopharma Credit Dividends - BPCR

[ADVERT]
Best deals to access real time data!
Silver
Monthly Subscription
for only
£17.37
Level 2 Basic
Monthly Subscription
for only
£62.08
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type
Biopharma Credit Plc BPCR London Ordinary Share
  Price Change Price Change % Stock Price Last Trade
0.002 0.21% 0.95 15:33:02
Open Price Low Price High Price Close Price Previous Close
0.952 0.95 0.952 0.95 0.948
more quote information »

Biopharma Credit BPCR Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
04/11/2021InterimUSX1.7530/03/202130/09/202118/11/202119/11/202117/12/20210
12/08/2021InterimUSX1.7502/03/202130/06/202119/08/202120/08/202117/09/20210
26/05/2021InterimUSX1.7531/03/202031/03/202119/08/202120/08/202117/09/20217.29
11/03/2021InterimUSX2.0431/08/202031/12/202018/03/202119/03/202116/04/20210
12/11/2020InterimUSX1.7530/03/202030/09/202019/11/202020/11/202018/12/20200
12/08/2020InterimUSX1.7501/03/202030/06/202020/08/202021/08/202018/09/20200
14/05/2020InterimUSX1.7531/03/201931/03/202021/05/202022/05/202019/06/20208.28
20/02/2020InterimUSX3.0331/08/201931/12/201927/02/202028/02/202027/03/20200
07/11/2019InterimUSX1.7530/03/201930/09/201914/11/201915/11/201917/12/20190
07/08/2019InterimUSX1.7502/03/201930/06/201915/08/201916/08/201920/09/20190
14/05/2019InterimUSX1.7531/03/201831/03/201923/05/201924/05/201921/06/20197.18
21/02/2019InterimUSX1.9331/08/201831/12/201828/02/201901/03/201929/03/20190
22/10/2018InterimUSX1.7530/03/201830/09/201801/11/201802/11/201830/11/20180
16/08/2018InterimUSX1.7502/03/201830/06/201830/08/201831/08/201828/09/20180
24/05/2018InterimUSX1.3431/03/201731/03/201831/05/201801/06/201829/06/20185.44
01/03/2018InterimUSX2.131/08/201731/12/201708/03/201809/03/201829/03/20180
07/12/2017InterimUSX130/03/201730/09/201714/12/201715/12/201731/01/20180
21/09/2017InterimUSX102/03/201730/06/201728/09/201729/09/201731/10/20170

Top Dividend Posts

DateSubject
22/10/2021
11:58
speedsgh: Net Asset Value(s) and Monthly Factsheet - HTTPS://uk.advfn.com/stock-market/london/biopharma-credit-BPCR/share-news/BioPharma-Credit-PLC-Net-Asset-Values-and-Monthly/86341206 As at the 30 September 2021 the unaudited net asset value per Ordinary Share, including current period revenue, was 99.62 cents. The Company's factsheet will be located on the Company's website, hxxp://bpcruk.com. [30/9/21: 99.62 cents per share] [31/8/21: 99.22 cents per share] [31/7/21: 100.38 cents per share] [30/6/21: 99.80 cents per share] [31/5/21: 100.93 cents per share] [30/4/21: 100.27 cents per share] [31/3/21: 99.85 cents per share] [28/2/21: 101.40 cents per share] [31/1/21: 100.84 cents per share] [31/12/20: 100.37 cents per share] [30/11/20: 99.91 cents per share] [31/10/20: 101.13 cents per share] [30/9/20: 101.00 cents per share]
03/10/2021
12:04
jonathan49: Hi, All of the credit ITs that I currently hold have an express policy to hedge overseas holdings back to GBP in the expectation that investors are GBP based. I see that BPCR is priced in $ which would be fine but on reading their literature I cannot see that there is any hedging in place. If so, then obviously the capital value would deteriorate in GBP if GBP were to strengthen vs. $. Is it correct that there is no hedging? Thanks,
21/9/2021
16:28
speedsgh: Net Asset Value(s) and Monthly Factsheet - HTTPS://uk.advfn.com/stock-market/london/biopharma-credit-BPCR/share-news/BioPharma-Credit-PLC-Net-Asset-Values-and-Monthly/86101788 As at the 31 August 2021 the unaudited net asset value per Ordinary Share, including current period revenue, was 99.22 cents. The Company's factsheet will be located on the Company's website, hxxp://bpcruk.com. [31/8/21: 99.22 cents per share] [31/7/21: 100.38 cents per share] [30/6/21: 99.80 cents per share] [31/5/21: 100.93 cents per share] [30/4/21: 100.27 cents per share] [31/3/21: 99.85 cents per share] [28/2/21: 101.40 cents per share] [31/1/21: 100.84 cents per share] [31/12/20: 100.37 cents per share] [30/11/20: 99.91 cents per share] [31/10/20: 101.13 cents per share] [30/9/20: 101.00 cents per share]
20/9/2021
19:24
williamcooper104: For WHT it's not where it's listed but where the tax residency of the parent company who pays the dividend is So for BPCR it's the UK (from memory it's not in the Channel Islands) thus no WHT AY (a renewable yield co) for instance is NYSE listed but tax resident in the UK and thus you get your dividends WHT free (Needless to say I am not a tax advisor - and rules do often change/get interpreted wrongly)
20/9/2021
19:10
tiltonboy: BPCR can be held in an ISA
20/9/2021
18:50
rogerramjett: Interested in investing here but wondered with this being a US listing are the dividend subject to withholding tax. I lost out on tax within my ISA when investing in CAC40 listed TotalEnergies and understand that with US traded stocks you can complete a form which reduces tax on dividends. Just not sure if it's applicable to BPCR as its an investment trust. If tax is with held what is this amount please ? Reading the previous post it mentions listing on LSE. Is this going ahead or in the pipeline? I assume this will eliminate any withholding tax concerns which ultimately reduce the yield. Thanks in advance.
15/9/2021
08:32
davebowler: Liberum; Mkt Cap £970m | Share price $0.98 | Prem/(disc) -2.8% | Div yield 7.5% Event BioPharma Credit's NAV per share at 30 June 2021 was 99.8 cents (previously reported), representing a NAV total return of 3.2% over H1. We estimate look-through recurring EPS of 3.7 cents (1.05x dividend cover) and a capital loss of 0.4 cents. The portfolio generated additional liquidity totalling $124m, including pre-payments. This included $97m from payments from the Sebela loan, including a final prepayment premium totalling $1.5m. The final payment was made on 30 June 2021, with BPCR realising an IRR of 11.2% on the investment. During H1, BPCR and BioPharma-V2 agreed a $300m senior secured term loan with LumiraDx, a UK based diagnostics company. LumiraDx is now the second largest loan in the portfolio behind Sarepta ($350m). At the period-end, BPCR's cash balance was $211.3m, representing 15.5% of NAV. Post-period end corporate updates for the BPCR included: Proposed main market listing - an application has been submitted to trade on the premium segment of the LSE. Continuation resolution brought forward - this has been brought forward by a year from the required five year mark to 30 September 2021 and will be held at the forthcoming AGM. RCF refinanced - the committed RCF with JPMorgan Chase has been reduced from $200m to $50m, while allowing for an increase up to $200m. The margin payable under the RCF has reduced from 4.00% to 2.75%. View BPCR has continued to generate a high level of income, despite the impact of cash drag, with credit quality remained materially unaffected by the pandemic. We believe the current 2.8% discount and 7.5% dividend yield are an attractive entry point for a high quality portfolio that has delivered consistent returns since launching in 2017. The recent corporate announcements should positively support sentiment. Life sciences companies will require substantial capital over the coming years, as the number of number of products undergoing clinical trials continues to grow. The manager continues to report a strong pipeline and the focus will be on deploying resources. The loans are typically structured to provide protection against cash drag from repayments in the form of prepayment fees and make-whole penalties. BPCR's origination pipeline is likely to be further supported by the growing need for acquisition financing. Global life sciences M&A volume over H1 totalled $111bn, a 516% increase on H120.
15/9/2021
06:42
speedsgh: Half-yearly Report - HTTPS://www.investegate.co.uk/biopharma-credit-plc--bpcr-/rns/half-yearly-report/202109150700047778L/
20/8/2021
21:12
speedsgh: Net Asset Value(s) - HTTPS://uk.advfn.com/stock-market/london/BPCR/share-news/BioPharma-Credit-PLC-Net-Asset-Values/85885768 As at the 31 July 2021 the unaudited net asset value per Ordinary Share, including current period revenue, was 100.38 cents. The Company's factsheet will be located on the Company's website, hxxp://bpcruk.com [31/7/21: 100.38 cents per share] [30/6/21: 99.80 cents per share] [31/5/21: 100.93 cents per share] [30/4/21: 100.27 cents per share] [31/3/21: 99.85 cents per share] [28/2/21: 101.40 cents per share] [31/1/21: 100.84 cents per share] [31/12/20: 100.37 cents per share] [30/11/20: 99.91 cents per share] [31/10/20: 101.13 cents per share] [30/9/20: 101.00 cents per share]
12/11/2020
11:42
speedsgh: Dividend Declaration - HTTPS://www.investegate.co.uk/biopharma-credit-plc--bpcr-/rns/dividend-declaration/202011120700060560F/ BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, is pleased to declare an interim dividend in respect of the financial period ending 30 September 2020 of $0.0175 per ordinary share and a small special dividend in respect of the financial period ending 31 December 2019 of $0.0001 per ordinary share, payable on 18 December 2020 to ordinary shareholders on the register as at 20 November 2020. The Company has a small revenue reserve remaining for the fiscal year 2019 that it is distributing to ordinary shareholders. The Company has chosen to designate the entire amount of this interim and special dividend as an interest distribution. Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest. This will result in a reduction in the corporation tax payable by the Company. The Company is currently paying and continues to target a 7 cent annual dividend per ordinary share.
ADVFN Advertorial
Your Recent History
LSE
BPCR
Biopharma ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211201 22:58:05